[go: up one dir, main page]

BRPI0607330A2 - composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto - Google Patents

composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto

Info

Publication number
BRPI0607330A2
BRPI0607330A2 BRPI0607330-1A BRPI0607330A BRPI0607330A2 BR PI0607330 A2 BRPI0607330 A2 BR PI0607330A2 BR PI0607330 A BRPI0607330 A BR PI0607330A BR PI0607330 A2 BRPI0607330 A2 BR PI0607330A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
individual
treating inflammation
preventing apoptosis
Prior art date
Application number
BRPI0607330-1A
Other languages
English (en)
Inventor
Hyun Ik Shin
Hyeong Wook Choi
Tae Ho Heo
Kyu Woong Lee
Jae Hoon Lee
Ki Sook Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BRPI0607330A2 publication Critical patent/BRPI0607330A2/pt
Publication of BRPI0607330B1 publication Critical patent/BRPI0607330B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

COMPOSTO, PROCESSO PARA PREPARAR O MESMO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR INFLAMAçãO OU PREVENIR APOPTOSE EM UM INDIVìDUO, E, USO DO COMPOSTO. A presente invenção diz respeito a um derivado de isoxazolina com a fração hemicetal do ácido carboxílico cíclica de fórmula (1) para uso como inibidor de caspase, um processo para prepará-lo e uma composição farmacêutica que o compreende.
BRPI0607330-1A 2005-02-26 2006-02-21 Composto, processo para preparar o mesmo, composição farmacêutica, e, uso do composto BRPI0607330B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2005-0016203 2005-02-26
KR20050016203 2005-02-26
PCT/KR2006/000576 WO2006090997A1 (en) 2005-02-26 2006-02-21 Isoxazoline derivative and novel process for its preparation

Publications (2)

Publication Number Publication Date
BRPI0607330A2 true BRPI0607330A2 (pt) 2009-09-29
BRPI0607330B1 BRPI0607330B1 (pt) 2021-08-03

Family

ID=36927605

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607330-1A BRPI0607330B1 (pt) 2005-02-26 2006-02-21 Composto, processo para preparar o mesmo, composição farmacêutica, e, uso do composto

Country Status (28)

Country Link
US (1) US8044080B2 (pt)
EP (1) EP1851214B1 (pt)
JP (1) JP4961357B2 (pt)
KR (1) KR100774999B1 (pt)
CN (1) CN101128459B (pt)
AP (1) AP2374A (pt)
AR (1) AR055314A1 (pt)
AU (1) AU2006217293B2 (pt)
BR (1) BRPI0607330B1 (pt)
CA (1) CA2598347C (pt)
DK (1) DK1851214T3 (pt)
EA (1) EA013005B1 (pt)
ES (1) ES2394480T3 (pt)
IL (1) IL185226A0 (pt)
MA (1) MA29311B1 (pt)
MX (1) MX2007010338A (pt)
MY (1) MY149181A (pt)
NO (1) NO341347B1 (pt)
NZ (1) NZ560805A (pt)
PE (1) PE20061076A1 (pt)
PL (1) PL1851214T3 (pt)
PT (1) PT1851214E (pt)
SG (1) SG156689A1 (pt)
SI (1) SI1851214T1 (pt)
TW (1) TWI377205B (pt)
UA (1) UA94395C2 (pt)
WO (1) WO2006090997A1 (pt)
ZA (1) ZA200707202B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
TW201012816A (en) * 2008-07-11 2010-04-01 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
TW201011014A (en) * 2008-07-11 2010-03-16 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP6118907B2 (ja) * 2012-09-28 2017-04-19 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 植物病害を防除するための窒素含有ヘテロ環式化合物
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
CN110177774B (zh) * 2017-01-23 2021-05-07 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
ES2980695T3 (es) * 2019-04-19 2024-10-02 Lg Chemical Ltd Profármaco de inhibidor de caspasas
JP7442914B2 (ja) * 2019-04-30 2024-03-05 エルジー・ケム・リミテッド カスパーゼ阻害剤のプロドラッグ
EP3970699A4 (en) * 2019-05-31 2022-08-10 LG Chem, Ltd. COMPOSITION FOR CASPASE INHIBITOR PRODRUG INJECTION
EP3970698A4 (en) * 2019-05-31 2022-08-31 LG Chem, Ltd. INJECTABLE COMPOSITION WITH PRODRUG OF CASPASE INHIBITORS AND METHOD OF MANUFACTURE THEREOF
EP4173622A4 (en) * 2020-08-05 2023-07-05 Lg Chem, Ltd. Use of caspase inhibitor for alleviating or treating osteoarthritis
WO2022114876A1 (ko) 2020-11-30 2022-06-02 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR102670554B1 (ko) * 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
CA3242627A1 (en) 2022-01-24 2023-07-27 Lg Chem, Ltd. Injectable formulation containing isoxazoline derivative
CN118574603A (zh) 2022-02-23 2024-08-30 株式会社Lg化学 包含异𫫇唑啉衍生物的注射制剂及其制备方法
WO2023182877A1 (ko) 2022-03-24 2023-09-28 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
KR19990079267A (ko) * 1998-04-03 1999-11-05 성재갑 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제
JP4195561B2 (ja) * 1999-09-17 2008-12-10 エルジー ケム インヴェストメント リミティッド カスパーゼインヒビター
AU5762899A (en) * 1999-09-17 2001-04-24 Lg Chemical Ltd. Caspase inhibitor
US7446127B2 (en) * 2003-08-27 2008-11-04 Sk Holdings Co, Ltd. Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제

Also Published As

Publication number Publication date
EP1851214B1 (en) 2012-09-05
PE20061076A1 (es) 2006-12-27
ZA200707202B (en) 2008-10-29
NO341347B1 (no) 2017-10-16
MA29311B1 (fr) 2008-03-03
AU2006217293B2 (en) 2012-02-02
DK1851214T3 (da) 2012-10-15
EP1851214A4 (en) 2009-10-28
CA2598347C (en) 2011-08-02
EP1851214A1 (en) 2007-11-07
CN101128459A (zh) 2008-02-20
UA94395C2 (ru) 2011-05-10
EA013005B1 (ru) 2010-02-26
PT1851214E (pt) 2012-10-18
AU2006217293A1 (en) 2006-08-31
HK1111146A1 (en) 2008-08-01
TWI377205B (en) 2012-11-21
EA200701810A1 (ru) 2008-02-28
US8044080B2 (en) 2011-10-25
JP2008531551A (ja) 2008-08-14
SG156689A1 (en) 2009-11-26
KR100774999B1 (ko) 2007-11-09
ES2394480T3 (es) 2013-02-01
AP2374A (en) 2012-03-07
MY149181A (en) 2013-07-31
US20080262032A1 (en) 2008-10-23
TW200640918A (en) 2006-12-01
MX2007010338A (es) 2007-10-11
PL1851214T3 (pl) 2013-03-29
BRPI0607330B1 (pt) 2021-08-03
JP4961357B2 (ja) 2012-06-27
SI1851214T1 (sl) 2012-11-30
NZ560805A (en) 2010-12-24
WO2006090997A1 (en) 2006-08-31
KR20060094868A (ko) 2006-08-30
NO20074895L (no) 2007-11-26
AR055314A1 (es) 2007-08-15
CA2598347A1 (en) 2006-08-31
IL185226A0 (en) 2008-02-09
CN101128459B (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
IL195030A (en) Dpp iv inhibitor formulations
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
BRPI0617165B1 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
BRPI0806365B8 (pt) composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
CR20110016A (es) Compuestos quimicos 251
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0808764B8 (pt) compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
BRPI0413848B8 (pt) composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, processo para preparar a composição terapêutica e uso de composto, ou de seu sal, ou de seu estereoisômero
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
CY1112191T1 (el) Παραγωγο πυραζολοπυριμιδινης
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
BRPI0607019A2 (pt) compostos que inibem a atividade de beta -secretase e métodos de uso dos mesmos
UY29510A1 (es) Derivados de urea, metodos para su fabricación, y usos de los mismos

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD. (KR)

B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD. (KR)

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 413/12

Ipc: C07D 413/12 (2006.01), A61P 29/00 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.